Company Profile
HK inno.N provides the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism.
Its portfolio also includes anemia and hemodialysis, diabetes, hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia, GERD, EE, NERD, GU and H.Pylori, pleural mesothelioma, non-small cell lung cancer, and mesothelioma, and colorectal cancer, and nutrition and intravenous nutrition
Health and beverage products, such as hangover relief, ready to drink, health supplements and health functional foods, as well as active pharmaceutical ingredients. Additionally, it offers beauty products under the bewants, ScalpMed, and KLEDERMA RX brands.
It also exports its products to Japan, Southeast Asia, Latin America, Europe, and the Middle East countries. The company has joint R&D agreement with Nextgen Bioscience for NXC680, a candidate compound for treatment of Idiopathic Pulmonary Fibrosis. Founded in 1984, HK inno.N is headquartered in Cheongju-si, South Korea.